ArticleCirculation. Cardiovascular quality and outcomes2021
Role of Frailty in Identifying Benefit From Transcatheter Versus Surgical Aortic Valve Replacement.
Article in Circulation. Cardiovascular quality and outcomes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- Association Between Claims-Defined Frailty and Outcomes Following 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Findings From the EXTEND-DAPT Study.Journal of the American Heart Association · 2023Trial
- Epicardial adipose tissue as an independent predictor of long-term outcome in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement.Clinical research in cardiology : official journal of the German Cardiac Society · 2025Article
- Development and internal validation of an age less-dependent frailty score in the cardiovascular health study.Frontiers in medicine · 2025Article
- Cardiac rehabilitation for TAVR patients: mechanisms, current status, and future directions.Frontiers in cardiovascular medicine · 2025Review
- Progression of frailty and cardiovascular outcomes among Medicare beneficiaries.Journal of the American Geriatrics Society · 2024Article
- Impact of frailty on outcomes and readmissions after transcatheter and surgical aortic valve replacement in a national cohort.JTCVS open · 2024Article
- A Comprehensive Geriatric Workup and Frailty Assessment in Older Patients with Severe Aortic Stenosis.Journal of clinical medicine · 2024Review
- Assessing the Benefits and Harms of Pharmacotherapy in Older Adults with Frailty: Insights from Pharmacoepidemiologic Studies of Routine Health Care Data.Drugs & aging · 2024Review
- Effect of Sex and Flow Status on Outcomes After Surgical or Transcatheter Aortic Valve Replacement.JACC. Advances · 2024Article
- Progression of Frailty and Cardiovascular Outcomes Among Medicare Beneficiaries.medRxiv : the preprint server for health sciences · 2024Article
- Depression and Malnutrition for Prediction of Mortality after Transcatheter Aortic Valve Replacement: A Registry Study of a Tertiary Referral Hospital.Diagnostics (Basel, Switzerland) · 2023Article
- Impact of frailty on disease-specific health status in cardiovascular disease.Heart (British Cardiac Society) · 2023Review
- Frailty and Recurrent Hospitalization After Transcatheter Aortic Valve Replacement.Journal of the American Heart Association · 2023Article
- Seeing the entire elephant: The challenges of frailty assessment for peripheral artery disease.Vascular medicine (London, England) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 1 country.
Funding
Abstract
backgroundFrailty is associated with a higher risk for adverse outcomes after aortic valve replacement (AVR) for severe aortic valve stenosis, but whether or not frail patients derive differential benefit from transcatheter (TAVR) versus surgical (SAVR) AVR is uncertain.
methodsWe linked adults ≥65 years old in the US CoreValve HiR trial (High-Risk) or SURTAVI trial (Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients) to Medicare claims, February 2, 2011, to September 30, 2015. Two frailty measures, a deficit-based and phenotype-based frailty index (FI), were generated. The treatment effect of TAVR versus SAVR was evaluated within FI tertiles for the primary end point of death and nondeath secondary outcomes, using multivariable Cox regression.
resultsOf 1442 (linkage rate =60.0%) individuals included, 741 (51.4%) individuals received TAVR and 701 (48.6%) received SAVR (mean age 81.8±6.1 years, 44.0% female). Although 1-year death rates in the highest FI tertiles (deficit-based FI 36.7% and phenotype-based FI 33.8%) were 2- to 3-fold higher than the lowest tertiles (deficit-based FI 13.4%; hazard ratio, 3.02 [95% CI, 2.26-4.02],
conclusionsTwo different frailty indices based on Fried and Rockwood definitions identified individuals at higher risk of death and functional impairment but no differential benefit from TAVR versus SAVR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.